On September 20, 2022, Evoke Pharma, Inc. announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 16/469,092 for the company's product, GIMOTI® (metoclopramide) nasal spray. The patent application, entitled “Treatment of Moderate and Severe Gastroparesis,” covers methods for treating moderate-to-severe gastroparesis with metoclopramide with an intranasal route of administration.

The U.S. patent scheduled to issue from this application will expire in 2039 and will be listed in the U.S. Food and Drug Administration's Orange Book.